Approved reimbursement uses for the device include wound care, soft tissue replacement as in burn repair, cardiovascular applications, treatment and ocular surfaces and surgical barrier application in knee and spine surgeries, according to a news release.
At this time, 12 state Medicaid programs also reimburse for EpiFix, according to the release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
